CSF1 receptor targeting in prostate cancer reverses macrophage-mediated resistance to androgen blockade therapy.

Journal Article (Journal Article)

Growing evidence suggests that tumor-associated macrophages (TAM) promote cancer progression and therapeutic resistance by enhancing angiogenesis, matrix-remodeling, and immunosuppression. In this study, prostate cancer under androgen blockade therapy (ABT) was investigated, demonstrating that TAMs contribute to prostate cancer disease recurrence through paracrine signaling processes. ABT induced the tumor cells to express macrophage colony-stimulating factor 1 (M-CSF1 or CSF1) and other cytokines that recruit and modulate macrophages, causing a significant increase in TAM infiltration. Inhibitors of CSF1 signaling through its receptor, CSF1R, were tested in combination with ABT, demonstrating that blockade of TAM influx in this setting disrupts tumor promotion and sustains a more durable therapeutic response compared with ABT alone.

Full Text

Duke Authors

Cited Authors

  • Escamilla, J; Schokrpur, S; Liu, C; Priceman, SJ; Moughon, D; Jiang, Z; Pouliot, F; Magyar, C; Sung, JL; Xu, J; Deng, G; West, BL; Bollag, G; Fradet, Y; Lacombe, L; Jung, ME; Huang, J; Wu, L

Published Date

  • March 15, 2015

Published In

Volume / Issue

  • 75 / 6

Start / End Page

  • 950 - 962

PubMed ID

  • 25736687

Pubmed Central ID

  • PMC4359956

Electronic International Standard Serial Number (EISSN)

  • 1538-7445

Digital Object Identifier (DOI)

  • 10.1158/0008-5472.CAN-14-0992


  • eng

Conference Location

  • United States